FDA Accepts BLA for Alvotech's AVT16, an Interchangeable Entyvio Biosimilar
ALVO sits 29% above its 52-week low of $2.94.
Summary
The FDA has accepted Alvotech's Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio. This is a significant regulatory milestone, moving a key pipeline asset closer to potential market approval. The 'interchangeable' designation is particularly valuable, as it allows for pharmacy-level substitution and enhances market potential. This follows recent positive regulatory news for other Alvotech biosimilars, signaling strong pipeline execution.
At the time of this announcement, ALVO was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $2.94 to $11.12. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.